natgillin/translations-raw huggingface dataset:
swelling of the limbs and face (peripheral oedema, facial oedema), sudden swelling of the face or throat with difficulties in breathing and/or itching and rash, often as an allergic reaction (angioneurotic oedema), allergic reactions, fever due to the administration of the medicine, serious allergic reaction which causes difficulty in breathing or dizziness (anaphylactic reaction) 
otekanje okončin in obraza (periferni edem, obrazni edem), nenadno otekanje obraza ali grla s težavami pri dihanju in/ali srbenjem in izpuščajem, pogosto kot alergijska reakcija (angionevrotični edem), alergijske reakcije, povečana telesna temperatura zaradi uporabe zdravila, resna alergijska reakcija, ki povzroči težave pri dihanju in omotico (anafilaktična reakcija)
• glibenclamide (used to treat diabetes). 
• Glibenklamid (uporablja se za zdravljenje sladkorne bolezni).
In that case the ciprofloxacin therapy must immediately be discontinued and an appropriate treatment initiated. 
V takšnem primeru je treba terapijo s ciprofloksacinom takoj prekiniti in uvesti ustrezno zdravljenje.
administration 62% is excreted unchanged in the urine and 15% is excreted in the faeces. 
Po intravenski uporabi se ga 62 % izloči nespremenjenega v urinu, 15 % pa se ga izloči v blatu.
Part of it is converted into desethylene-, sulpho-, oxoand formylciprofloxacin. 
Del se ga spremeni v dezetilen-, sulfo-, okso in formilciprofloksacin.
The transaminase or alkaline phosphatase concentrations may temporarily increase or cholestatic icterus might occur, especially in patients with previous liver damage. 
Pojavi se lahko prehodno zvišanje vrednosti transaminaz ali alkalne fosfataze ali pa holestatski ikterus, zlasti pri bolnikih, ki že imajo okvaro jeter.
fainting (syncope), widening of blood vessel (vasodilation) 
omedlevica (sinkopa) razširitev krvnih žil (vazodilatacija)
Ciprofloxacin is effective in vitro against a large number of Gram-negative aerobic bacteria including P. aeruginosa. 
Ciprofloksacin je in vitro učinkovit proti številnim gramnegativnim aerobnim bakterijam, vključno s P. aeruginosa.
It affects the lungs, sweat glands and the digestive system causing chronic respiratory and digestive problems. 
Prizadene pljuča, žleze znojnice in prebavila ter povzroča kronične težave v dihalih in prebavilih.
The applicant/MAH performed a review of published clinical studies from the mid 1990's to date, to support the recommended posology of 200-400 mg ciprofloxacin twice daily in the treatment of complicated urinary tract infections. 
Vlagatelj/imetnik dovoljenja za promet je opravil pregled objavljenih kliničnih raziskav od sredine 1990-ih let do današnjega dne, da bi podprl predlagani način odmerjanja z odmerki od 200 do 400 mg ciprofloksacina dvakrat dnevno za zdravljenje zapletenih primerov okužbe sečil.
No accumulation occurs on repeated administration (twice daily). 
Po ponavljajoči se uporabi (dvakrat na dan) ne pride do kopičenja.
The ciprofloxacin concentration in blister fluid, lymph, nasal secretion, peritoneal fluid, saliva and fatty tissue is approximately half of the serum concentration. 
Koncentracija ciprofloksacina v tekočini mehurjev, limfi, nosnih izločkih, peritonealni tekočini, slini in maščobnem tkivu je približno polovična od koncentracije v serumu.
Most frequent adverse reactions involve the gastro-intestinal tract and the central nervous system. 
Najpogostejši neželeni učinki vključujejo prebavila in centralni živčni sistem.
The usual dose in adults is 200-400 mg of ciprofloxacin twice daily. 
Običajni odmerek pri odraslih je 200-400 mg ciprofloksacina dvakrat na dan.
In that case, the ciprofloxacin treatment must be discontinued, and medical treatment for shock should be given. 
V takšnem primeru je treba zdravljenje s ciprofloksacinom prekiniti in uporabiti medicinsko terapijo šoka.
Like with other gyrase inhibitors, ciprofloxacin may induce joint damage during the growth phase of juvenile animals. 
Kot ostali zaviralci giraze ciprofloksacin lahko inducira poškodbe sklepov v fazi rasti mladih živali.
For the treatment of acute pulmonary infections caused by Pseudomonas aeruginosa bacteria in children and adolescents (5-17 years) with cystic fibrosis 15 mg of ciprofloxacin per kg body weight is administered twice daily or 10 mg ciprofloxacin per kg body weight is administered thrice daily (maximum 1200 mg daily). 
Za zdravljenje akutne okužbe spodnjih dihal, ki jih povzroča Pseudomonas aeruginosa, pri otrocih in mladostnikih (5-17 let) s cistično fibrozo se daje 15 mg ciprofloksacina na kg telesne mase dvakrat dnevno ali 10 mg ciprofloksacina na kg telesne mase trikrat dnevno (največ 1200 mg dnevno).
Within the class of quinolones cross-resistance has been observed. 
Navzkrižno odpornost so opažali znotraj kinolonske skupine.
Very rare: haemolytic anaemia, pancytopenia, agranulocytosis. 
Zelo redki: hemolitična anemija, pancitopenija, agranulocitoza.
Eye disorders: Rare: disturbed vision, diplopia, chromatopsia. 
Očesne bolezni: Redki: motnje vida, diplopija, kromatopsija.
The conditions studied were severe pneumonia, neutropenia, acute bacterial exacerbations of chronic bronchitis, complicated, community-acquired skin and skin structure infections, infections in cancer patients and bacteraemia,. 
Raziskana bolezenska stanja vključujejo hudo pljučnico, neutropenijo, akutno bakterijsko poslabšanje kroničnega bronhitisa, zapletene izvenbolnišnično pridobljene okužbe kože in kožnih struktur, okužbe bolnikov z rakom in bakteriemijo.
Ciprofloxacin Kabi is contraindicated in: - patients with a hypersensitivity to ciprofloxacin, chinolin carboxylic acid derivatives or to any of the excipients - children under 5 years of age. 
4.3 Kontraindikacije Ciprofloxacin Kabi je kontraindiciran pri: - bolnikih s preobčutljivostjo za ciprofloksacin, derivate kinolinkarboksilne kisline ali katerokoli pomožno snov v zdravilu, - otrocih mlajših od 5 let starosti.
ANNEX II SCIENTIFIC CONCLUSIONS AND GROUNDS FOR AMENDMENT OF THE SUMMARIES OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET PRESENTED BY THE EMEA 
DODATEK II ZNANSTVENI ZAKLJUČKI IN PODLAGA ZA DOPOLNILO POVZETKA GLAVNIH ZNAČILNOSTI ZDRAVILA, OZNAČEVANJA IN NAVODIL ZA UPORABO, KI JIH JE PREDSTAVILA EVROPSKA AGENCIJA ZA ZDRAVILA
Stenotrophomonas maltophilia Other pathogens Ureaplasma urealyticum Anaerobes 
Stenotrophomonas maltophilia Ostali povzročitelji Ureaplasma urealyticum Anaerobi
Ciprofloxacin is rapidly and effectively absorbed after oral administration. 
Ciprofloksacin se po peroralni uporabi hitro in učinkovito absorbira.
clinical data and discuss the risk/benefit of the proposed dose in urinary tract infections (UTI). 
Klinične podatke in razpravo o tveganjih in koristnih učinkih predlaganega odmerka pri okužbah sečil.
If you suffers from this disease, you should consult your doctor. 
Če imate to bolezen, se posvetujte z zdravnikom;
The duration of treatment with Ciprofloxacin Kabi is based on the severity of the infection, the effect of the treatment and the sensitivity of the pathogen(s). 
Trajanje zdravljenja z zdravilom Ciprofloxacin Kabi temelji na resnosti okužbe, učinku zdravljenja in občutljivosti povzročitelja (povzročiteljev).
ringing in the ear (tinnitus), transient hearing loss (particularly high frequencies) Heart disorders 
zvonjenje v ušesih (tinitus), prehodna izguba sluha (predvsem pri visokih frekvencah)
According to EUCAST the following breakpoints for aerobic bacteria have been defined for ciprofloxacin: - Enterobacteriaceae: ≤0.5 µg/ml for susceptible, >1 µg/ml for resistant; - Pseudomonas spp. 
Po priporočilih EUCAST so določene naslednje mejne vrednosti za aerobne bakterije za ciprofloksacin: - Enterobacteriaceae: ≤0,5 µg/ml za občutljive, >1 µg/ml za rezistentne; - Pseudomonas spp.
Therefore, the use of ciprofloxacin in children is generally not recommended, except for cystic fibrosis patients (see section 4.1). 
Glede uporabe ciprofloksacina pri otrocih in mladostnikih ni dovolj podatkov, zato uporaba ciprofloksacina pri otrocih na splošno ni priporočljiva, razen za bolnike s cistično fibrozo (glejte poglavje 4.1).
≤0.5 µg/ml for susceptible, >1 µg/ml for resistant; - Acinetobacter spp. 
≤0,5 µg/ml za občutljive, >1 µg/ml za rezistentne; - Acinetobacter spp.
Ciprofloxacin is a quinolone effective in vitro against a large number of Gram-negative aerobic bacteria as well as against some Gram-positive organisms. 
Ciprofloksacin je kinolon, ki je in vitro učinkovit proti številnim gramnegativnim aerobnim bakterijam kot tudi nekaterim grampozitivnim organizmom.
Like all medicines, Ciprofloxacin Kabi can cause side effects, although not everybody gets them. 
Kot vsa zdravila ima lahko tudi zdravilo Ciprofloxacin Kabi neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
The Ciprofloxacin Kabi dosage is based on the severity and type of the infection, the sensitivity of the pathogen(s), your age, weight and kidney function. 
Odmerjanje zdravila Ciprofloxacin Kabi temelji na resnosti in vrsti okužbe, občutljivosti povzročitelja (povzročiteljev), starosti, telesni masi in delovanju ledvic.
Very rare: tendinitis (in particular of the Achilles tendon), partial or total tendon ruptures (in particular of the Achilles tendon), aggravation of the symptoms of myasthenia. 
Zelo redki: tendinitis (zlasti Ahilove kite), delna ali popolna pretrganja kit (zlasti Ahilove kite), poslabšanje nekaterih simptomov miastenije.
≤1 µg/ml for susceptible, >1 µg/ml for resistant; - H. influenza and M. catarrhalis ≤0.5 µg/ml for susceptible, >0.5 µg/ml for resistant; - Neisseria gonorrhoeae: ≤0.03 µg/ml for susceptible, >0.06 µg/ml for resistant; - N. meningitides: ≤0.03 µg/ml for susceptible, >0.06 µg/ml for resistant; Non-species related breakpoints are ≤0.5 µg/ml for susceptible, and >1 µg/ml for resistant organisms. 
≤1 µg/ml za občutljive, >1 µg/ml za rezistentne; - H. influenza in M. catarrhalis ≤0,5 µg/ml za občutljive, >0,5 µg/ml za rezistentne; - Neisseria gonorrhoeae: ≤0,03 µg/ml za občutljive, >0,06 µg/ml za rezistentne; - N. meningitides: ≤0,03 µg/ml za občutljive, >0,06 µg/ml za rezistentne; Neodvisno od vrste so mejne vrednosti ≤0,5 µg/ml za občutljive, in >1 µg/ml za rezistentne organizme.
No clinical studies in the treatment of complicated or life-threatening urinary tract infections with the high 1200mg [or 1500 mg peroral] maximum dose proposed, were included or reviewed. 
Vlagatelj tudi ni pregledal ali vključil kliničnih raziskav o zdravljenju zapletenih ali življenjsko nevarnih okužb sečil s predlaganim visokim odmerkom, ki znaša največ 1200 mg [ali 1500 mg peroralno].
Clear flexible polyolefine bag with aluminium overpouch. 
Prozorna fleksibilna poliolefinska vrečka z aluminijskim zunanjim ovojem.
The bioavailability of ciprofloxacin after oral administration is between 70 % and 85 %. 
Po peroralni uporabi je biološka uporabnost ciprofloksacina med 70 in 85 %.
In case of any symptom indicating an exacerbation of myastenia gravis, you should therefore consult your doctor. 
Če se pojavi kakršen koli simptom, ki kaže na poslabšanje miastenije gravis, se posvetujte z zdravnikom;
Ciprofloxacin Kabi contains 15.1 mmol (347 mg) sodium per 100 ml solution for infusion. 
Ciprofloxacin Kabi vsebuje 15,1 mmol (347 mg) natrija v 100 ml raztopine za infundiranje.
B-2627 Schelle, Belgium Tel-No.: 0032 3 880 5024 Fax.No. 
B-2627 Schelle, Belgija Tel-No.: 0032 3 880 5024 Fax.No.
• patients with a history of tendon disorder related to fluoroquinolone administration 
• bolniki z anamnezo poškodbe kite, povezane z uporabo fluorokinolona,
• glucose-6-phosphate dehydrogenase defect (hereditary disease of the red blood cells based on a defect in an enzyme). 
• Okvara glukoza-6-fosfat dehidrogenaze (dedna bolezen eritrocitov, ki temelji na okvari encima).
• Store the infusion bag in the overpouch until it is used in order to protect from light. 
• Infuzijska vrečka naj ostane v zunanjem ovoju, dokler ni pripravljena za uporabo, za zagotovitev zaščite pred svetlobo.
Fresenius Kabi Austria GmbH, Hafnerstraße 36, A-8055 Graz, Austria Tel-No.: 0043 316 249 524 Fax.No. 
Fresenius Kabi Austria GmbH, Hafnerstraße 36, A-8055 Graz, Avstrija Tel-No.: 0043 316 249 524 Fax.No.
Important information about some of the ingredients of Ciprofloxacin Kabi If you are on a low-sodium diet, take into account that 100 ml of Ciprofloxacin Kabi contain 15.1 mmol (= 347 mg) sodium. 
Če ste na dieti z malo natrija, upoštevajte, da 100 ml zdravila Ciprofloxacin Kabi vsebuje 15,1 mmol (= 347 mg) natrija.
With regard to the safety and use of ciprofloxacin in children, see also section 4.4 - Children and growing adolescents except for the treatment of acute pulmonary exacerbations of cystic fibrosis in children aged 5 to 17 years. 
Glede varnosti in uporabe ciprofloksacina pri otrocih glejte tudi poglavje 4.4, - otrocih in odraščajočih mladostnikih, starih od 5-17 let, razen za zdravljenje akutnega poslabšanja pljučne cistične fibroze, - nosečnosti in dojenju, - bolnikih z anamnezo poškodbe kite povezane z dajanjem fluorokinolona.
Very rare: parosmia (impaired smell), anosmia (usually reversible after interruption), grand mal convulsion, abnormal (unstable) gait, intracranial hypertension. 
Zelo redki: parozmija (prizadetost voha), anozmija (ponavadi reverzibilna po prekinitvi zdravila), konvulzije grand mal, nenormalna (nestabilna) hoja, intrakranialna hipertenzija.
Following concomitant administration of ciprofloxacin and cyclosporine a transient increase of the serum creatinine concentration has been observed in separate cases. 
V posameznih primerih so po sočasni uporabi ciprofloksacina in ciklosporina opazili prehodno zvišanje koncentracije kreatinina v serumu.
Gram-negative aerobes 
Grampozitivni aerobi
On concurrent administration of ciprofloxacin and caffeine or pentoxifylline (oxpentifylline), raised serum concentrations of these xanthine derivatives were reported. 
Ob sočasnem dajanju ciprofloksacina in kofeina ali pentoksifilina (oksipentifilina) so poročali o zvišanju koncentracij ksantinskih derivatov v serumu.
Ciprofloxacin exerts a rapid bactericidal effect by inhibiting DNA-gyrase, resulting in inhibition of DNA synthesis. 
Ciprofloksacin ima hiter baktericidni učinek zaradi zaviranja DNA-giraze in s tem posledično sinteze DNA.
Simultaneous administration of ciprofloxacin and mexiletine can lead to increased plasma concentrations of mexiletine. 
Sočasno dajanje ciprofloksacina in meksiletina lahko vodi do povečanja koncentracije meksiletina v plazmi.
Probenecid inhibits the renal excretion of ciprofloxacin resulting in an increase in the plasma concentration of ciprofloxacin. 
Probenecid inhibira izločanje ciprofloksacina skozi ledvica kar ima za posledico povečanje koncentracije ciprofloksacina v plazmi.
EXPIRY DATE EXP (MM/YYYY) 
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA EXP (MM/YYYY)
distorted sensation of taste, dizziness, headache, difficulty in sleeping (insomnia), restlessness (agitation), confusion 
motnje okušanja, omotica, glavobol, težave pri spanju (nespečnost), nemir (agitacija), zmedenost
Ciprofloxacin inhibits this enzyme. 
Ciprofloksacin zavira ta encim.
Ciprofloxacin Kabi is used for the treatment of severe and/or life-threatening infections caused by ciprofloxacin-sensitive microorganisms. 
Ciprofloxacin Kabi je indiciran za zdravljenje resnih in/ali smrtno nevarnih okužb, ki jih povzročajo za ciprofloksacin občutljivi mikroorganizmi.
• The other ingredients are sodium chloride, sulphuric acid, sodium hydroxide for pH adjustment, water for injections 
• Pomožne snovi so: natrijev klorid, žveplova kislina, natrijev hidroksid za uravnavanje pH in voda za injekcije.
Dose adjustment according to renal function. 
Odmerek se prilagodi glede na delovanja ledvic.
If you have kidney problems you should inform your doctor. 
Če imate težave z ledvicami, o tem obvestite zdravnika.
Streptococcus pyogenes 
Streptococcus pyogenes Gramnegativni aerobi
Very rare: moniliasis (gastro-intestinal), pancreatitis. 
Zelo redki: kandidoza (gastrointestinalna), pankreatitis.
Mutagenicity of ciprofloxacin has not been indicated in mutagenicity studies. 
Študije mutagenosti niso pokazale, da bi bil ciprofloksacin mutagen.
In patients on haemodialysis or CAPD, the maximum daily intravenous dose is also 400 mg. On the dialysis days, the dose is given after the haemodialysis session. 
Tudi pri bolnikih na hemodializi ali kontinuirani ambulantni peritonealni dializi je venski odmerek 400 mg. Na dan dialize mora bolnik odmerek dobiti po hemodializi.
Fresenius Kabi Deutschland GmbH,D-61346 Bad Homburg v.d.H.,Germany Tel-No.: 0049 6172 686 0 Fax.No. 
Fresenius Kabi Deutschland GmbH,D-61346 Bad Homburg v.d.H.,Nemčija Tel-No.: 0049 6172 686 0 Fax.No.
Very rare: vasculitis (petechiae, hemorrhagic bullae, papules, crust formation). 
Zelo redki: vaskulitis (petehije, hemoragične bulozne spremembe, papule, nastajanje krast).
Rare: taste loss (reduced taste), paraesthesia (peripheral paralgesia), tremor (shaking), convulsions, migraine. 
Redki: zmanjšanja sposobnost okušanja, parestezije (periferna paralgezija), tremor (tresenje), konvulzije, migrena.
Uncommon: (thrombo)phlebitis. 
Občasni: (trombo)flebitis.
Ear and labyrinth disorders: Rare: tinnitus, transient hearing loss (particularly high frequencies). 
Ušesne bolezni, vključno z motnjami labirinta: Redki: tinitus, prehodna izguba sluha (zlasti v področju visokih frekvenc).
Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin potentially leading to increased plasma levels of methotrexate. 
Renalni tubularni transport metotreksata je lahko inhibiran s sočasnim dajanjem ciprofloksacina kar potencialno vodi do povečanja koncentracije metotreksata v plazmi.
The pharmacokinetics of ciprofloxacin in children with cystic fibrosis differs from that in children without cystic fibrosis, and dosing recommendations are only applicable for children with cystic fibrosis. 
Farmakokinetika ciprofloksacina se pri otrocih s cistično fibrozo razlikuje od farmakokinetike otrok, ki niso oboleli za cistično fibrozo.
• phenytoin (used to treat epilepsy). 
• Fenitoin (uporablja se za zdravljenje epilepsije).
Ciprofloxacin is potentially neurotoxic and causes reversible defects of the testes in case of higher dosage. 
Ciprofloksacin je potencialno nevrotoksičen in v velikih odmerkih povzroči reverzibilne okvare mod.
≤1 µg/ml for susceptible, >1 µg/ml for resistant; - S. pneumonia ≤0.125 µg/ml for susceptible, >2 µg/ml for resistant; - Staphylococcus spp. 
≤1 µg/ml za občutljive, >1 µg/ml za rezistentne; - S. pneumonia ≤0,125 µg/ml za občutljive, >2 µg/ml za rezistentne; - Staphylococcus spp.
Ciprofloxacin may inhibit the excretion of methotrexate via the kidney, causing an increased methotrexate level in the blood. 
Ciprofloksacin lahko zavira izločanje metotreksata prek ledvic, kar povzroči zvišano koncentracijo metotreksata v krvi.
In patients with epilepsy or other lesions of the central nervous system (e.g. reduced convulsion threshold, a history of epileptic seizures, diminished cerebral bloodflow, changes in brain structure or stroke), ciprofloxacin is only to be used after carefully weighing the benefits against the risk, because the possibility of central nervous side effects puts these patients at increased risk. 
Pri bolnikih z epilepsijo ali drugimi motnjami osrednjega živčevja (npr. nižjim pragom za konvulzije, anamnezo epileptičnih napadov, zmanjšanim pretokom krvi v možganih, spremembah v zgradbi možganov ali možgansko kapjo) uporabite ciprofloksacin le po natančnem pretehtanju koristi in tveganj.
Crystalluria related to the use of ciprofloxacin has been reported. 
Poročali so o kristaluriji povezani z uporabo ciprofloksacina.
You must not be given Ciprofloxacin Kabi during pregnancy. 
Med nosečnostjo ne smete dobivati zdravila Ciprofloxacin Kabi.
Very rare: hepatitis, liver cell necrosis (very rarely resulting in life-threatening liver function failure). 
Zelo redki: hepatitis, nekroza jetrnih celic (ki zelo redko povzroči smrtno nevarno odpoved jeter)
Acute lower respiratory tract infections caused by Pseudomonas aeruginosa in children and adolescents (5-17years) with cystic fibrosis: 
Akutne okužbe spodnjih dihal, ki jih povzroča Pseudomonas aeruginosa, pri otrocih in mladostnikih (5-17 let) s cistično fibrozo:
Ciprofloxacin (as hydrogen sulphate) 
Ciprofloksacin (v obliki ciprofloksacinijevega hidrogensulfata)
a life-threatening condition characterised by a sharp drop in the blood pressure, paleness, restlessness, weak/quick pulse, clammy skin, dizziness as a result of severe allergy to this medicine (anaphylactic shock), itching rash, fever, joint swellings, muscle pains, rash (symptoms similar to those occurring in a disease called serum sickness) 
Zelo redki življenjsko nevarno stanje, za katero so značilni hiter padec krvnega tlaka, bledica, nemir, šibek/hiter srčni utrip, vlažna koža, omotica, kar je posledica alergije na to zdravilo (anafilaktični šok), srbeč izpuščaj, povečana telesna temperatura, otekanje sklepov, bolečine v mišicah, izpuščaj (simptomi so podobni tistim, ki se pojavijo pri bolezni, imenovani serumska bolezen)
• probenecid (used to treat gout). 
• Probenecid (uporablja se za zdravljenje protina).
Rare: tachycardia. 
Redki: tahikardija.
The CHMP has recommended the granting of the Marketing Authorisation(s) for which the Summary of Product Characteristics, labelling and package leaflet are set out in Annex III for Ciprofloxacin Kabi and associated names (see Annex I). 
CHMP je za Ciprofloxacin Kabi in z njim povezana imena (glej Dodatek I) priporočil odobritev dovoljenj(a) za promet, katerih Povzetek glavnih značilnosti zdravila, označevanje in Navodila za uporabo so opredeljeni v Dodatku III.
Up to now, no evidence has been found of an increased risk of congenital abnormalities or other undesirable effects following use of ciprofloxacin or other quinolones during the first trimester. 
Doslej po uporabi ciprofloksacina oz. drugih kinolonov v prvem trimesečju nosečnosti niso ugotovili večjega tveganja za prirojene nepravilnosti ali druge neželene učinke.
Rare in more than 1 in 10,000 patients, but less than 1 in 1,000 patients 
Redki pri več kot 1 od 10.000 bolnikov, vendar manj kot 1 od 1.000 bolnikov
• children and growing adolescents except for the treatment of acute lower respiratory tract infections caused by Pseudomonas aeruginosa bacteria in children and adolescents aged 5-17 years with cystic fibrosis 
• otroci in odraščajoči mladostniki, razen za zdravljenje akutne okužbe spodnjih dihal, ki jih povzroča Pseudomonas aeruginosa, pri otrocih in mladostnikih, starih med 5 in 17 let, s cistično fibrozo,
After oral administration ciprofloxacin is excreted unchanged for approx. 70% and after i.v. 
Po peroralni uporabi se ciprofloksacin izloči nespremenjen v približno 70 %, po intravenski uporabi pa v približno 77 %.
Common in more than 1 in 100 patients, but less than 1 in 10 patients 
Pogosti pri več kot 1 od 100 bolnikov, vendar manj kot 1 od 10 bolnikov
Twice daily intravenous administration of 15 mg/kg bodyweight, or 10 mg/kg bodyweight three times daily (maximum of 1200 mg per day). 
Intravenska aplikacija 15 mg/kg telesne mase dvakrat na dan ali 10 mg/kg telesne mase trikrat na dan (največ 1200 mg na dan).
Uncommon: increase of blood creatinine levels, increased blood urea; abnormal liver function test results (increased SGOT and SGPT), bilirubinemia and increased alkaline phosphatase. 
Občasni: povišanje ravni kreatinina v krvi, povečanje sečnine v urinu, nenormalne vrednosti jetrnih testov (povišan SGOT in SGPT), bilirubinemija in povečanje vrednosti alkalne fosfataze.
Read all of this leaflet carefully before you start using this medicine. 
Pred začetkom uporabe natančno preberite navodilo!
Therefore, in case of any symptom indicating an exacerbation of Myastenia gravis a physician must be consulted. 
Zato se je treba v primeru kakršnegakoli simptoma, ki kaže na poslabšanje miastenije gravis, posvetovati z zdravnikom.